Publication Spotlight: Comprehensive Review on Circulating C1QC in Cancer

A new narrative review published in Clinica Chimica Acta examines the potential of circulating complement C1q C chain, known as C1QC, as a biomarker for various solid tumors. The work, titled Circulating C1QC in cancer: analytical platforms, evidence gaps, and prospects for clinical chemistry translation, provides a detailed assessment of current analytical methods, existing limitations in the data, and steps needed for broader clinical adoption. Authored by Isam M. Abu Zeid, Muhammad Afzal, Misbahuddin Rafeeq, Mustafa Zeyadi, Kamel Chaieb, Hisham N. Altayb, Sami I. Alzarea, Muhammad Shahid Nadeem, and Imran Kazmi, the review appears in the June 2026 issue and is available at the original publication.

This publication arrives at a time when traditional serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), cancer antigen 125 (CA-125), alpha-fetoprotein (AFP), and prostate-specific antigen (PSA) continue to show constraints in early detection and specificity across overlapping cancer types. Researchers have turned attention to components of the complement system, with C1QC emerging as a molecule of interest due to its connections to classical pathway activation and tumor-associated macrophage behavior.

Defining C1QC and Its Biological Context

C1QC refers to the C chain subunit of the C1q complex, which initiates the classical complement pathway. This pathway forms part of the innate immune system and responds to immune complexes, apoptotic cells, and altered self-ligands often present on tumor cells. Unlike broader measurements of total C1q or C1q-binding activity, specific quantification of the C1QC protein in circulation requires targeted assays that distinguish it from related subunits C1QA and C1QB.

The gene encoding C1QC resides on chromosome 1p36.12 alongside C1QA and C1QB, with coordinated expression regulated in part by the transcription factor PU.1 in macrophages. In the tumor microenvironment, C1QC expression has been associated with M2-like polarization of tumor-associated macrophages, which can contribute to immunosuppressive conditions and metabolic reprogramming. These associations stem from transcriptomic and single-cell studies across multiple cancer types, though direct links to circulating protein levels require further protein-specific validation.

Key Findings on Diagnostic Performance

The review synthesizes evidence suggesting that serum C1QC measurements can enhance diagnostic area under the curve (AUC) values across seven major solid tumor types. When incorporated into multimarker panels alongside established markers such as CEA, CA 19-9, CA-125, and PSA, C1QC appears to provide incremental value in distinguishing malignant from benign conditions. These observations build on earlier bioinformatics analyses and smaller cohort studies that identified C1QC transcript associations with tumor stage, lymph node involvement, and overall survival in cancers including colon adenocarcinoma, osteosarcoma, and clear cell renal cell carcinoma.

Mechanistic insights point to C1QC-positive macrophages influencing immune infiltration and, in some contexts, promoting tumor progression through complement-mediated signaling. However, the review emphasizes that many supporting data originate from tissue-level transcriptomics rather than direct circulating protein quantification, underscoring the need for protein-focused clinical studies.

Analytical Platforms for C1QC Measurement

Several technology platforms receive evaluation for their suitability in clinical chemistry laboratories. Traditional immunoassays have historically measured total C1q or functional binding activity rather than the specific C1QC chain, which can lead to interpretive challenges. Newer approaches include targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods capable of distinguishing proteoforms and post-translational modifications.

Aptamer-based electrochemical biosensors show promise for point-of-care applications, offering rapid quantification with potential for integration into routine workflows. Surface plasmon resonance platforms provide another avenue for sensitive detection in research settings. The review compares analytical performance metrics across these methods, highlighting trade-offs in sensitivity, specificity, throughput, and ease of standardization.

Photo by National Cancer Institute on Unsplash

Evidence Gaps and Methodological Challenges

Significant gaps remain before C1QC can transition into routine clinical use. Pre-analytical variables such as sample handling, storage conditions, and interference from inflammatory or infectious states require systematic study. External quality assessment schemes and assay harmonization efforts are currently limited for this analyte.

Most available clinical associations derive from retrospective or small prospective cohorts, with few multicenter validations. Reference intervals in healthy populations show age- and sex-dependent variations, yet comprehensive pediatric and adult normative data specific to C1QC remain incomplete. Regulatory pathways under the In Vitro Diagnostic Medical Devices Regulation (IVDR) in Europe and United States Food and Drug Administration (FDA) frameworks demand robust analytical and clinical validation data that are still in development.

Prospects for Clinical Chemistry Translation

The review outlines a roadmap for advancing C1QC toward clinical adoption. Priorities include development of certified reference materials, establishment of metrological traceability, and conduct of prospective multicenter trials that directly measure circulating C1QC protein. Integration with existing laboratory information systems and automation compatibility will also prove essential for widespread laboratory implementation.

Point-of-care biosensor formats could expand access in resource-limited settings or for serial monitoring during treatment. The authors stress that successful translation hinges on closing standardization gaps and generating high-quality evidence demonstrating clinical utility beyond current markers.

Implications for Research and Laboratory Practice

For clinical chemists and oncology researchers, this publication highlights opportunities to refine biomarker panels and explore complement components in liquid biopsy contexts. Laboratories interested in expanding their test menus may consider pilot studies using validated immunoassays or mass spectrometry workflows while awaiting further standardization.

Academic institutions and research centers can leverage these insights to design studies addressing the identified evidence gaps, potentially fostering collaborations between clinical chemistry departments, oncology teams, and diagnostic industry partners. The work also underscores the importance of distinguishing between transcript-level findings and protein measurements in biomarker discovery pipelines.

Broader Context in Cancer Biomarker Development

Complement pathway proteins have attracted increasing attention as researchers seek analytes that reflect both tumor biology and host immune responses. C1QC fits within a growing group of innate immunity markers under investigation for their roles in the tumor microenvironment and systemic circulation. Parallel studies on other complement components, such as C4d and C3, provide complementary perspectives on pathway activation.

Advances in single-cell technologies and spatial transcriptomics continue to refine understanding of C1QC-expressing macrophage subsets, which may inform future assay development. The review positions C1QC within this evolving landscape while cautioning against overinterpretation of preliminary associations.

Photo by Giovanni Crisalfi on Unsplash

Future Directions and Research Opportunities

Looking ahead, the field would benefit from harmonized protocols for C1QC quantification and large-scale biobanking efforts that enable retrospective and prospective analyses. Investigations into the complosome—the intracellular complement system—and its potential contribution to circulating levels represent an emerging area of inquiry.

Integration of C1QC data with other omics layers, including metabolomics and proteomics of tumor-educated macrophages, could yield more robust predictive models. Regulatory science initiatives focused on novel biomarkers will play a key role in accelerating responsible translation.

Conclusion and Outlook

The narrative review by Abu Zeid and colleagues offers a balanced, framework-driven evaluation of circulating C1QC that moves the conversation from discovery toward clinical chemistry application. While promising signals exist for improved diagnostic performance in multimarker settings, substantial work remains to address analytical standardization, evidence quality, and regulatory requirements. Researchers and laboratory professionals can use this synthesis as a foundation for targeted studies that advance the field responsibly. The full text provides detailed discussions of gene structure, proteoform considerations, and platform comparisons that will interest specialists in clinical chemistry and oncology diagnostics.